2,567 results on '"Kumar, Shaji K."'
Search Results
2. Genetically determined telomere length in monoclonal gammopathy of undetermined significance, multiple myeloma risk and outcome
3. Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma
4. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms
5. Long term responders in frontline multiple myeloma—exception vs expectation of the modern era
6. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
7. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
8. Mode of progression in smoldering multiple myeloma: a study of 406 patients
9. Whole-body low-dose computed tomography in patients with newly diagnosed multiple myeloma predicts cytogenetic risk: a deep learning radiogenomics study
10. Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
11. Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma – updated results after 18-year follow-up
12. Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100
13. Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment
14. Retreatment of multiple myeloma with previously refractory drugs
15. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
16. Identification of novel genetic loci for risk of multiple myeloma by functional annotation
17. An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
18. New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma
19. Muscle and fat composition in patients with newly diagnosed multiple myeloma
20. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
21. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
22. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
23. Utility of flow cytometry screening before MRD testing in multiple myeloma
24. A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
25. Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma
26. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
27. Conditional survival in multiple myeloma and impact of prognostic factors over time
28. Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma
29. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
30. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
31. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment
32. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
33. Percutaneous Cryoablation of Plasmacytomas: Oncologic Effectiveness and Adverse Events
34. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
35. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
36. Outcomes after biochemical or clinical progression in patients with multiple myeloma
37. Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
38. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
39. Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method
40. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
41. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.
42. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
43. Decoding DNA methylation in epigenetics of multiple myeloma
44. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
45. Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
46. Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders
47. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis
48. Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100
49. Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma
50. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.